Menu Philippe sold $29K of SOPH
Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $5.70 on 2026-07-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CMO’s open-market sale details (5,000 shares at $5.7010) executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure reduces signal strength versus a non-plan sale.
What to watch
The article does not state whether other insiders sold/bought, nor does it quantify total insider activity or compare to prior Form 4 patterns.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS.
Ticker impact
SOPHiA GENETICS CMO Menu Philippe sold 5,000 shares on 2026-07-13 under a pre-arranged 10b5-1 plan at $5.7010.
Likely minimal near-term impact; any effect is more sentiment than fundamentals.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and it provides no new company-specific operational or financial information.
Market effects
No clear sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
Insider sales under 10b5-1 often reflect planned liquidity needs rather than bearish expectations.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction disclosure.
- insiderMenu Philippe
Chief Medical Officer who sold shares under a 10b5-1 plan.
